358 related articles for article (PubMed ID: 33841966)
21. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
[TBL] [Abstract][Full Text] [Related]
22. Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer.
Hu Y; Ren SY; Wang RY; Zeng C; Li JN; Xiao P; Wu F; Yu FL; Liu WL
Front Oncol; 2021; 11():684070. PubMed ID: 34692476
[TBL] [Abstract][Full Text] [Related]
23. Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer.
Tao Y; Li X; Liu B; Wang J; Lv C; Li S; Wang Y; Chen J; Yan S; Wu N
Front Oncol; 2023; 13():1135140. PubMed ID: 37256186
[TBL] [Abstract][Full Text] [Related]
24. Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer.
Wu J; Hou L; E H; Zhao Y; Yu X; Xu L; Ning Y; Deng J; Sun K; Zhang J; Wu C; Zhu Y; Zhao D; She Y; Su C; Chen C
Lung Cancer; 2022 Mar; 165():115-123. PubMed ID: 35123154
[TBL] [Abstract][Full Text] [Related]
25. [The efficacy and safety of immunotherapy combined with chemotherapy neoadjuvant in locally advanced resectable hypopharyngeal squamous cell carcinoma].
Wang K; Zhang W; Gui L; He XH; Wang JB; Lu HZ; Li DZ; Liu C; Guo ZZ; Xu M; Liu SY; Wang XL
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):343-349. PubMed ID: 38599640
[No Abstract] [Full Text] [Related]
26. Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Meta-analysis.
Xu J; Yan C; Li Z; Cao Y; Duan H; Ke S
Ann Surg Oncol; 2023 Mar; 30(3):1597-1613. PubMed ID: 36380254
[TBL] [Abstract][Full Text] [Related]
27. Tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxel-based regimens, squamous cell carcinoma, and comorbidities were independently associated with efficacy of neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Hu X; Hu C; Liu X; Ma F; Xie J; Zhong P; Tang C; Fan D; Gao Y; Feng X; Ding M; Li D; Liu C
Front Oncol; 2022; 12():1057646. PubMed ID: 36776373
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer.
Zhao ZR; Yang CP; Chen S; Yu H; Lin YB; Lin YB; Qi H; Jin JT; Lian SS; Wang YZ; You JQ; Zhai WY; Long H
Oncoimmunology; 2021; 10(1):1996000. PubMed ID: 34712513
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE).
Duan H; Shao C; Pan M; Liu H; Dong X; Zhang Y; Tong L; Feng Y; Wang Y; Wang L; Newman NB; Sarkaria IS; Reynolds JV; De Cobelli F; Ma Z; Jiang T; Yan X
Front Immunol; 2022; 13():849984. PubMed ID: 35720388
[TBL] [Abstract][Full Text] [Related]
30. Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer.
Tong BC; Gu L; Wang X; Wigle DA; Phillips JD; Harpole DH; Klapper JA; Sporn T; Ready NE; D'Amico TA
J Thorac Cardiovasc Surg; 2022 Feb; 163(2):427-436. PubMed ID: 33985811
[TBL] [Abstract][Full Text] [Related]
31. Is response evaluation criteria in solid tumors (RECIST) effective in patient selection for radical resection after neoadjuvant immunotherapy with advanced NSCLC?
Xu Y; Ma D; Qin Y; Li S; Li J; Jiang Y; Wang M; Xu Y; Zhao J; Chen M; Cheng W; Hu K; Liu H
Thorac Cancer; 2023 Jun; 14(17):1635-1639. PubMed ID: 37094918
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Provencio M; Nadal E; Insa A; García-Campelo MR; Casal-Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Casarrubios M; Salas Antón C; Parra ER; Wistuba I; Calvo V; Laza-Briviesca R; Romero A; Massuti B; Cruz-Bermúdez A
Lancet Oncol; 2020 Nov; 21(11):1413-1422. PubMed ID: 32979984
[TBL] [Abstract][Full Text] [Related]
33. Dose-dense Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy for Stage IIB/IIIA Non-small Cell Lung Cancer - A Phase II trial.
Mittal A; Malik PS; Kumar S; Saikia J; Chitikela S; Khurana S; Bharti S; Jain D; Pathy S; Thulkar S; Kumar R; Madan K; Mohan A
Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):e553-e560. PubMed ID: 34340919
[TBL] [Abstract][Full Text] [Related]
34. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Langer CJ; Gadgeel SM; Borghaei H; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Ge Y; Raftopoulos H; Gandhi L;
Lancet Oncol; 2016 Nov; 17(11):1497-1508. PubMed ID: 27745820
[TBL] [Abstract][Full Text] [Related]
35. Short-term outcomes of neoadjuvant sintilimab with chemotherapy in stage III non-small cell lung cancer: a case series.
Fan BS; Wang XT; Di SY; Zhao JH; Chen SY; Zhou SH; Yue CY; Song WA; Gong TQ
Transl Cancer Res; 2022 Jun; 11(6):1697-1704. PubMed ID: 35836545
[TBL] [Abstract][Full Text] [Related]
36. Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
Zhang C; Hong HZ; Wu YL; Zhong WZ
JTCVS Open; 2021 Dec; 8():588-607. PubMed ID: 36004199
[TBL] [Abstract][Full Text] [Related]
37.
Xu X; Shi Z; Fu D; Huang D; Ma Z
Front Oncol; 2022; 12():1008932. PubMed ID: 36338754
[TBL] [Abstract][Full Text] [Related]
38. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322
[TBL] [Abstract][Full Text] [Related]
39. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma.
Wu Z; Zheng Q; Chen H; Xiang J; Hu H; Li H; Pan Y; Peng Y; Yao X; Liu P; Sun Y; Li B; Zhang Y
J Thorac Dis; 2021 Jun; 13(6):3518-3528. PubMed ID: 34277047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
